Loeb Cuts, Highland Boosts Stakes In PDL Battle

Nov 5 2007 | 3:39pm ET

In response to what it says are insufficient measures taken by portfolio company PDL BioPharma, activist hedge fund Third Point has cut its stake in the company almost in half. But another activist hedge fund with similar demands has stepped up its pressure on the Fremont, Calif.-based company.

In a letter to PDL’s board, Daniel Loeb, founder of the New York-based hedge fund, said he had cut his fund’s stake from 9.7% to 5.1% “in light of your continuing refusal to provide us with a voice in the company’s affairs through a board seat.” Loeb has long sought a sale of PDL, and said he was “encouraged” by the board’s announcement it would actively seek such a sale. But he ripped Chairman Patrick Gage, who has served as interim CEO since former CEO and Loeb nemesis Mark McDade resigned this summer, saying he has “demonstrated his unsuitability” for the post.

Unfortunately for the maligned Gage and his cohorts on the board, Loeb’s retreat coincided with the advance of another activist seeking major changes at the company. Dallas-based Highland Capital Management took a 5.2% stake in PDL over the past few months, and fired off a letter in September—filed with the Securities and Exchange Commission last week—with its own set of strident demands.

Highland President Jim Dondero doesn’t just want Gage to give up the CEO’s role; he wants him out entirely, demanding that he resign as chairman, and calling on the board to name former chairman and CEO Laurence Korn to succeed him. In addition, Highland wants an independent director named to fill a vacancy on the board, and for the process of selling the company to be expedited.

“We have attempted to, and will remain available to, discuss the recommendations put forth in this letter,” Dondero assured. But he went on, “That said, we believe the time for dialogue has ended and encourage each of you to honor your fiduciary obligations to the company and its shareholders by expeditiously implementing our recommendations in order to protect shareholder value.”


In Depth

Kettera Q&A: The Advantages of Alternative Investment Platforms

Oct 28 2016 | 5:52pm ET

The past several years have seen a distinct push towards easier and cheaper access...

Lifestyle

Midtown's Plaza District Fades As Manhattan Office Landscape Shifts

Nov 22 2016 | 6:32pm ET

Lower leasing costs, more efficient office space and the hope of projecting an image...

Guest Contributor

Nowhere to Hide: Why the Future of Asset Management Depends on Innovation

Nov 15 2016 | 6:55pm ET

Information technology has reshaped the asset management industry’s periphery,...

 

From the current issue of

Chicago-based independent futures brokerage and clearing firm R.J. O’Brien & Associates (RJO) has hired industry veteran Daniel Staniford as Executive Director, responsible for the firm’s institutional business development in New York and London.

AVAILABLE NOW at BARNES & NOBLE

NEWSTAND LOCATOR